Featured post

SCS research and awards news

For all our research and awards news, please visit our news page.

Monday 11 April 2016

Hudson Special Seminar - 12 April: "GD2-specific CAR T cell theapy for metastatic melanoma"

Prof Michael Brown, Director of Cancer Clinical Trials Unit, Senior Medical Oncologist at Royal Adelaide Hospital Cancer Centre, Clinical Professor, School of Medicine, University of Adelaide will talk about "GD2-specific CAR T cell theapy for metastatic melanoma".

Tuesday 12 April, 2.30-3.30pm, Boardrooms A & B, Level 3, Hudson Building

Light refreshments to follow presentation outside the Boardrooms.


In a bench to bedside effort, researchers in the Translational Oncology Laboratory are applying advances in immunotherapeutic technologies to the treatment of melanoma, myeloid leukemia, brain and lung cancers, which affect millions around the world. The two major technologies of interest are chimeric antigen receptors (CARs) for re-directing lymphocytes toward cancers and antibody drug conjugates (ADCs) for targeting potent cytotoxins to cancers.

We are developing pre-clinical and clinical approaches for the treatment of these cancers to aid in diagnosis, therapy monitoring and treatment. Much of our research is collaborative, working in association with the RAH Cancer Clinical Trials Unit and partnering with other laboratories within the Centre for Cancer Biology.

No comments:

Post a Comment